Arcutis Biotherapeutics, Inc. (ARQT)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Arcutis Biotherapeutics, Inc. reported revenue of $372.07M, up 123.4% from the prior year. The company ran a net loss, with a net margin of -4.3%. It held $432.97M in total assets against $243.49M in total liabilities.
Key ratios (FY2025)
-3.3%
Operating margin
-4.3%
Net margin
-8.5%
Return on equity
+123.4%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $372.07M | $166.54M | $29.19M | $3.69M | $0 | $0 | — | — | — |
| Cost of Revenue | $36.70M | $19.13M | $4.99M | $754.0K | $0 | — | — | — | — |
| Operating Income | -$12.23M | -$128.40M | -$241.10M | -$301.63M | -$206.53M | -$136.65M | -$43.13M | -$19.73M | — |
| Net Income | -$16.14M | -$140.04M | -$262.14M | -$311.46M | -$206.36M | -$135.68M | -$42.00M | -$19.25M | — |
| EPS (Diluted) | $-0.13 | $-1.16 | $-3.78 | $-5.66 | $-4.18 | $-3.80 | $-22.78 | — | — |
| Total Assets | $432.97M | $348.89M | $341.37M | $449.27M | $408.15M | $298.27M | $107.01M | — | — |
| Total Liabilities | $243.49M | $191.35M | $252.70M | $239.69M | $110.47M | $27.65M | $5.55M | — | — |
| Shareholders' Equity | $189.48M | $157.54M | $88.67M | $209.58M | $297.68M | $270.62M | -$65.03M | -$23.99M | -$4.99M |
| Cash & Equivalents | $42.91M | $71.33M | $88.39M | $53.64M | $96.45M | $65.08M | $63.34M | — | — |
| Operating Cash Flow | -$5.62M | -$112.16M | -$247.06M | -$257.71M | -$174.63M | -$113.03M | -$42.84M | -$14.09M | — |
| Capital Expenditures | $686.0K | $143.0K | $428.0K | $333.0K | $995.0K | $321.0K | $295.0K | $0 | — |
| Shares Outstanding | 123.33M | 117.85M | 96.79M | 61.04M | 50.26M | 43.34M | 2.12M | — | — |